LMB-9 Immunotoxin in Treating Patients With Advanced Solid Tumors - Related Studies

LMB-9 Immunotoxin in Treating Patients With Advanced Solid Tumors

This study has been completed.

Study NCT00019435. Last updated on October 18, 2008. Information provided by National Cancer Institute (NCI)

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Bladder Cancer
		Breast Cancer
		Colorectal Cancer
		Esophageal Cancer
		Gastric Cancer
		Lung Cancer
		Pancreatic Cancer

2	Additional conditions recognized in this trial
		Breast Neoplasms
		Colorectal Neoplasms
		Esophageal Diseases
		Esophageal Neoplasms
		Lung Neoplasms
		Pancreatic Neoplasms
		Stomach Neoplasms
		Urinary Bladder Neoplasms

3	More general conditions related to this trial
		Breast Diseases
		Colonic Diseases
		Digestive System Diseases
		Digestive System Neoplasms
		Endocrine Gland Neoplasms
		Endocrine System Diseases
		Gastrointestinal Diseases
		Gastrointestinal Neoplasms
		Head and Neck Neoplasms
		Intestinal Diseases
		Intestinal Neoplasms
		Lung Diseases
		Neoplasms
		Neoplasms by Site
		Pancreatic Diseases
		Rectal Diseases
		Respiratory Tract Diseases
		Respiratory Tract Neoplasms
		Skin Diseases
		Stomach Diseases
		Thoracic Neoplasms
		Urinary Bladder Diseases
		Urogenital Neoplasms
		Urologic Diseases
		Urologic Neoplasms

4	Interventions listed in this trial
		LMB-9 immunotoxin

5	Additional drug interventions recognized in this trial
		Immunotoxins

6	More general drug interventions related to this trial
		Immunologic Factors
		Pharmacologic Actions
		Physiological Effects of Drugs

7	Sponsors listed in this trial
		NCI - Center for Cancer Research-Medical Oncology
		National Cancer Institute (NCI)